Open Label Prostate Cancer Study
2016年1月11日 更新者:AstraZeneca
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.
The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)
調査の概要
研究の種類
介入
入学 (実際)
64
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
20年~130年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
男
説明
Inclusion Criteria:
- Males aged 20 years or older.
- Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate.
- Documented evidence of metastatic prostate cancer
- Presence of progressive disease defined as one or more:
- Biochemical progression of the prostate cancer
- Progression as defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines
- Two or more new metastatic bone lesions from bone scans from a previous assessment
- Serum testosterone concentration less or equals 50 ng/dL
- World Health Organization (WHO) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.
- Sexually active males should be willing to use condoms
- For inclusion in the AZD3514 administered in combination with abiraterone acetate cohort(s), patients must:
- Have received prior chemotherapy containing or based on docetaxel
- Not have received prior treatment with abiraterone acetate, MDV3100, TAK700, TOK001 or other similar therapies which target the AR axis or with selective AR down-regulator-like properties
For inclusion in the AZD3514 administered in combination with abiraterone acetate in patients who are currently receiving abiraterone acetate cohort(s), patients must:
- Have been stable on abiraterone acetate abiraterone acetate for ≥ 4 months (i.e. stable PSA values) and have achieved ≥ 50% reduction in PSA while being treated with abiraterone acetate
- Have evidence of biochemical progression (PSA) of the prostate cancer, as defined in inclusion number 5 (except for the withdrawal of abiraterone acetate as an anti-androgen therapy)
For inclusion in the paired (same lesion) tumour biopsy research, patients must:
- Provide informed consent for paired tumour biopsy sampling
- Have bone or soft tissue lesions that are suitable for paired biopsy sampling
Exclusion Criteria:
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAEv4) grade 1 except for alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists
- Medically important spinal cord compression or brain metastases
- Medically important evidence of severe or uncontrolled systemic disease
- History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD3514
- Inadequate bone marrow reserve or organ function
- Any medically important factors identified from electrocardiogram (ECG) measurements
- Concurrent or recent treatment with certain medications or medical procedures
The following criteria exclude patients from entering the AZD3514 administered in combination with abiraterone acetate cohort(s):
- As judged by the investigator, any evidence of severe or uncontrolled systemic diseases or conditions, including adrenocortical insufficiency or a history of cardiovascular disease including heart failure (currently there are no randomized data for the use of abiraterone acetate in patients with LVEF < 50% or NYHA Class III or IV heart failure), which would make it undesirable for the patient to participate in the trial. See the full local prescribing information for abiraterone acetate for more detail
- Child-Pugh class B and C hepatic impairment
- If unable to fast for ≥ 2 hours prior to taking a dose to ≥ 1 hour post dose
- Received abiraterone acetate treatment previously
- Known hypersensitivity to components of prednisone or prednisolone
- Any systemic fungal infections
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:A
Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
|
Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
To investigate the safety and tolerability of AZD3514 when given orally to patients with CRPC.
時間枠:At every visit.
|
At every visit.
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
To define the MTD, if possible, a lower biologically-effective dose(s) or maximum feasible dose (if decided by the Safety Review Committee (SRC) and AstraZeneca).
時間枠:After each Cohort.
|
After each Cohort.
|
|
To characterise the PK of AZD3514 after a single oral dose and at steady state after multiple oral doses.
時間枠:After each Cohort.
|
After each Cohort.
|
|
To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).
時間枠:Visits 1, 4, 6, 7, 9, 10, follow-up visits, discontinuation visit
|
Visits 1, 4, 6, 7, 9, 10, follow-up visits, discontinuation visit
|
|
To obtain a preliminary assessment of the anti-tumour activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate by evaluation of counts of Circulating Tumour Cells (CTCs).
時間枠:Visits 1, 6, 8, 9, 10, follow-up visits, discontinuation visit
|
Visits 1, 6, 8, 9, 10, follow-up visits, discontinuation visit
|
|
To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).
時間枠:Visits 1, 10, follow-up visits, discontinuation visit
|
Visits 1, 10, follow-up visits, discontinuation visit
|
|
To investigate safety, tolerability, MTD (and/or biologically-effective dose(s) or maximum feasible dose) and PK of AZD3514 and abiraterone when administered in combination, in patients who have not received prior treatment with abiraterone acetate
時間枠:At every visit
|
At every visit
|
|
To compare the PK of AZD3514 monotherapy in patients who have been fed or fasted before the administration of study treatment
時間枠:At visits 2 and 4
|
At visits 2 and 4
|
|
To investigate the effect of AZD3514 on biomarkers of AR expression in paired pre- and post-dose tumour biopsies.
時間枠:July 2012 - Feb 2013
|
July 2012 - Feb 2013
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- スタディディレクター:Glen Clack, MD、AstraZeneca
- 主任研究者:Tony Elliott, MD、The Christie Hospital
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2010年8月1日
一次修了 (実際)
2013年3月1日
研究の完了 (実際)
2015年10月1日
試験登録日
最初に提出
2010年7月13日
QC基準を満たした最初の提出物
2010年7月13日
最初の投稿 (見積もり)
2010年7月14日
学習記録の更新
投稿された最後の更新 (見積もり)
2016年1月12日
QC基準を満たした最後の更新が送信されました
2016年1月11日
最終確認日
2016年1月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。